| Literature DB >> 35482954 |
Giulia Iannelli, Ciro Milite, Nils Marechal1,2,3,4, Vincent Cura1,2,3,4, Luc Bonnefond1,2,3,4, Nathalie Troffer-Charlier1,2,3,4, Alessandra Feoli, Donatella Rescigno, Yalong Wang5, Alessandra Cipriano, Monica Viviano, Mark T Bedford5, Jean Cavarelli1,2,3,4, Sabrina Castellano, Gianluca Sbardella.
Abstract
Protein arginine methyltransferases (PRMTs) are important therapeutic targets, playing a crucial role in the regulation of many cellular processes and being linked to many diseases. Yet, there is still much to be understood regarding their functions and the biological pathways in which they are involved, as well as on the structural requirements that could drive the development of selective modulators of PRMT activity. Here we report a deconstruction-reconstruction approach that, starting from a series of type I PRMT inhibitors previously identified by us, allowed for the identification of potent and selective inhibitors of PRMT4, which regardless of the low cell permeability show an evident reduction of arginine methylation levels in MCF7 cells and a marked reduction of proliferation. We also report crystal structures with various PRMTs supporting the observed specificity and selectivity.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35482954 PMCID: PMC9469100 DOI: 10.1021/acs.jmedchem.2c00252
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 8.039